ALK and lung carcinoma: Based on the discoveries of ALK as an important oncogene and the encoded fusion protein in development of different cancers, a search for small molecular ALK-tyrosine kinase inhibitors (TKIs) identified Crizotinib (PF-02341066) as the first in class compound receiving FDA-approval for treatment of ALK-positive advanced lung cancer in 2011 [20].